These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 27776977)

  • 1. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
    Zibelman M; Ramamurthy C; Plimack ER
    Urol Oncol; 2016 Dec; 34(12):538-547. PubMed ID: 27888981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Thibault C
    Bull Cancer; 2018 Dec; 105 Suppl 1():S43-S49. PubMed ID: 30595198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
    Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
    Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    Dhariwal R; Pindoria N; Dasgupta P; Khan MS
    BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune checkpoint inhibitors: a new frontier in bladder cancer.
    Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
    World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
    Schmid SC; Koll FJ; Beckert F; Seitz AK
    Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.